The FASEB Journal · 2004 · 175 citations · 33 references
Life SciencesCardiologyImmunologyCardiac TransplantationImmunoregulationTransplant ImmunologyAllograft RejectionHeart TransplantationTransplant ImmunotherapyTransplant PharmacologyTransplant RejectionGraft Survival EnhancementHeme CatabolismImmunologic Response To AllograftLeukocyte FunctionLeukocyte ProliferationLong-term Graft SurvivalNatural Product PharmacologyTransplant Tolerance Mechanisms
Biliverdin, a product of heme oxygenase-1 (HO-1) enzymatic action, is converted into bilirubin, which has been considered a waste product in the past. We now show that administration of biliverdin has a salutary effect in organ transplantation. A brief course of treatment with biliverdin leads to long-term survival of H-2 incompatible heart allografts. Furthermore, those recipients harboring long-surviving (>100 days) allografts were tolerant to donor antigens indicated by the acceptance of second donor strain hearts but not third-party grafts. Treatment with biliverdin decreased intragraft leukocyte infiltration and inhibited T cell proliferation. Likely related to tolerance induction, biliverdin interferes with T cell signaling by inhibiting activation of nuclear factor of activated T cells (NFAT) and nuclear factor kappaB (NF-kappaB), two transcription factors involved in interleukin-2 (IL-2) transcription and T cell proliferation, as well as suppressing Th1 interferon-gamma (IFN-gamma) production in vitro. These findings support the potential use of biliverdin, a natural product, in transplantation and other T cell mediated immune disorders.
33
Bilirubin Is an Antioxidant of Possible Physiological Importance
Roland Stocker, Yorihiro Yamamoto, Antony F. McDonagh et al. · Science · 1987 · 3.5K citations
PRIMARILY VASCULARIZED ALLOGRAFTS OF HEARTS IN MICE
Robert J. Corry, Henry J. Winn, Paul S. Russell · Transplantation · 1973 · 793 citations
Life Sciences, Immunology, Surgery +17